Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-label, Randomized, PK and Safety Study To Assess Bronchopulmonary Disposition of Intravenous TP-6076 in Healthy Men and Women

Trial Profile

A Phase 1, Open-label, Randomized, PK and Safety Study To Assess Bronchopulmonary Disposition of Intravenous TP-6076 in Healthy Men and Women

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Dec 2018

At a glance

  • Drugs TP 6076 (Primary)
  • Indications Bacterial infections
  • Focus Pharmacokinetics
  • Acronyms BAL
  • Sponsors Tetraphase Pharmaceuticals
  • Most Recent Events

    • 10 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 08 Nov 2018 According to a Tetraphase Pharmaceuticals media release, this study is expected to start in 1Q 2019.
    • 08 Nov 2018 Planned initiation date changed from 1 Nov 2018 to 1 Jan 2019, according to a Tetraphase Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top